Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback